Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register
about
Advances in rheumatology: new targeted therapeuticsLong-term safety and efficacy of infliximab for the treatment of ankylosing spondylitisWhat is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Tuberculosis vaccines: barriers and prospects on the quest for a transformative toolThe Value of Patient-Centred Registries in Phase IV Drug SurveillanceEtanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.Biologics registers in RA: methodological aspects, current role and future applications.Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.Discordant inflammation and pain in early and established rheumatoid arthritis: Latent Class Analysis of Early Rheumatoid Arthritis Network and British Society for Rheumatology Biologics Register data.Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database.Listeria meningitis and resultant symptomatic hydrocephalus complicating infliximab treatment for ulcerative colitis.Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studiesFulminant legionellosis in two patients treated with infliximab for Crohn's disease: case series and literature review.Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in AsiaTen years with biologics: to whom do data on effectiveness and safety apply?Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study.Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.TNF-α Antagonist and Infection in Rheumatoid Arthritis.Initiation of rheumatoid arthritis treatments and the risk of serious infections.Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study.Validity of self-report of infections in a longitudinal cohort of patients with rheumatoid arthritis differs by source of report and infection severity.Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapyUpdate on the treatment of ankylosing spondylitis.Update of the management of chronic psoriasis: new approaches and emerging treatment options.Crosstalk between sentinel and helper macrophages permits neutrophil migration into infected uroepithelium.Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritisEpidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with speciaRates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy.Infliximab: 12 years of experienceLower extremity ulcers in rheumatoid arthritis: features and response to immunosuppressionTumor necrosis factor blockade and the risk of viral infectionAdverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis
P2860
Q21093257-98CB7939-C5BB-4E27-9933-3835A20927A4Q26774173-9CAA2240-4800-482D-9654-D837FFE8FED8Q28074148-0D9C0A98-51ED-46BD-819A-C351DB1F13B9Q28390218-2DB4C976-2BE2-482E-A3E7-6BE1671A7A7AQ29395899-85296A95-E603-4CC0-AD36-6F8DA80E71D0Q30009390-E78D77B4-6D28-41C4-AE4B-1A341EE685D1Q30234303-EDFC01FD-AA7A-4947-B963-6CA9E3CCBE0CQ30240183-D14DFA65-C15D-491A-8490-2D87620E7E88Q30680371-60A2C5A1-4B8A-417F-8112-B1229490745CQ30725001-CEC7978F-6643-445A-B00B-D1406069AFF2Q31123685-5F905CE6-0B05-4F98-8F60-8E98EFB56A36Q31148620-0C979E20-DECE-427A-B2BE-65A2DD999830Q33529391-EE561769-B456-49D5-A951-4EC85348EBACQ33576604-7D50651E-E59A-4D14-AFC2-98E19FC027D5Q33578361-DCFCAEF5-8A19-45E7-AB1F-FB227438F7F1Q33586890-A056ADD5-C974-4BF5-B113-74590EBF90D5Q33667789-63FA472A-7A6D-4622-821C-C2B4A1D2B594Q33749195-91913E87-7F34-4FF6-82AF-0215B62D83EEQ33778719-8D2885AB-B361-43D5-84E0-D01F5E2C81F1Q33792680-1F305080-35BE-4D5F-B4E8-3B0DFEF3BC69Q33819684-D4952DB5-684E-4C0E-AFD3-A264A68B518FQ33872130-4009F9E6-7D30-4124-9DCB-AC82DE6C2902Q34019267-CA82C7F3-272D-4FAC-BEED-0B43661B9791Q34065002-D4F7F546-2FA5-4979-8F2C-E6AF86C206F6Q34065405-1E19CDEF-7F74-4AB8-AA5D-11FC7B7B9D73Q34153015-B8B1D251-2426-42C8-B417-BD0FB7E64BA8Q34195402-BF904290-C2A2-4B2C-A05A-90227E5BA3DEQ34413227-EF3ABF92-85ED-45A3-A4A4-E24B84947AA5Q34592673-4B752847-DF0D-4DD0-BD40-D7C32A769228Q34620375-00A28B0D-D999-416D-969B-7E5FF252D915Q34643625-EF081561-97CE-440B-A085-D5F99DD17C19Q34756501-BE2FBAAE-B954-47BC-BD43-F6742521AA9AQ34792330-B77EFCB2-B94B-446A-B1B7-8DF94E6FD615Q34986307-CC6100E5-5723-498F-8C55-B68E360BEB55Q35018415-FC1D65A8-1B07-4DF4-B0CC-5A628419C908Q35048101-39F9205D-5AE4-4078-8690-FEB0A10A2E68Q35070446-A9FB9910-08DA-40A1-80E6-35CBA78B8A1EQ35084344-5637A169-F87F-49EB-B50E-C0DA400CE5B7Q35161630-2437A092-EE07-4E97-B42F-A74693B44F11Q35170882-9EF77A80-69CF-43C2-BC52-76A557FD307F
P2860
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register
description
scientific article published on 01 August 2006
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2006
@uk
name
Rates of serious infection, in ...... heumatology Biologics Register
@en
Rates of serious infection, in ...... heumatology Biologics Register
@nl
type
label
Rates of serious infection, in ...... heumatology Biologics Register
@en
Rates of serious infection, in ...... heumatology Biologics Register
@nl
prefLabel
Rates of serious infection, in ...... heumatology Biologics Register
@en
Rates of serious infection, in ...... heumatology Biologics Register
@nl
P2093
P50
P921
P356
P1476
Rates of serious infection, in ...... heumatology Biologics Register
@en
P2093
A J Silman
British Society for Rheumatology Biologics Register
K L Hyrich
P304
P356
10.1002/ART.21978
P577
2006-08-01T00:00:00Z